Kornimate/medical-research-clean huggingface dataset:
dynamic ultrasonography vs mri in the evaluation of meniscal lesions in patients with an indication for arthroscopy

Conditions: Meniscus Lesion; Meniscus Disorder; ACL Injuries

Summary: this is a diagnostic, open-label, single-center interventional study. this study aims to evaluate the diagnostic accuracy of dynamic ultrasonography for meniscal injuries in patients with an indication for arthroscopy, and to compare it with the study in mri.

patients admitted for acl injury and indication for arthroscopy will be included in a study involving the evaluation of the diagnostic accuracy of dynamic ultrasound compared with mri. a total of 254 patients will be included, who after providing their signed informed consent to participate in the study, will undergo dynamic ultrasound. after giving signed consent to participate in the study, the patient will undergo the ultrasound evaluation for assessment of possible meniscal injury; radiological examinations in the patient's possession or from the patient's medical record will be collected during or before the diagnostic investigation.

Eligibility criteria:
inclusion criteria: patients with an indication for knee arthroscopy with: 1. age between 18 and 60 years; 2. unilateral involvement; 3. presence of symptomatology such that dynamic ultrasound examination is precluded; 4. ability and consent of patients to actively participate in the study; exclusion criteria: 1. patients unable to express consent; 2. patients with malignant neoplasms; 3. patients with rheumatic diseases; 4. patients with diabetes; 5. patients with metabolic disorders of the thyroid gland; 6. patients abusing alcoholic beverages, drugs or medications; 7. body mass index \> 35; 8. pregnant or lactating women;

Keywords: dynamic ultrasonography arthroscopy mri interventional trial
clopidogrel maintaining dosage in acute coronary syndrome after drug eluting stent implantation

Conditions: Acute Coronary Syndrome

Summary: in view of its safety profile and the results of clinical trials, clopidogrel has become the standard treatment for patients with acute coronary syndrome (acs) and drug eluting stent(des) implantation. two large studies in patients with acs shown that pretreatment with clopidogrel had beneficial effects. the pretreatment regimens were given a mean of 6 days before intervention in the observational pci-cure trial and 3 to 24 h in the randomized credo trial respectively. accordingly, current clinical practice carries out pretreatment with a 300mg loading dose of clopidogrel at least 6 h before des implantation procedure in patients with acs. compared with the 300mg clopidogrel loading dose, 600mg loading dose exhibited a superior antiplatelet effect and improved short-term clinical outcomes in patients undergoing des implantation for acs according to recent a few publications. but despite clopidogrel 600mg loading dose and the routine use of 75mg per day as a maintaining dose, recurrent ischemic events occurred in some patients. therefore, the goal of this study will evaluate the efficacy of a 600mg loading dose of clopidogrel plus 150mg per day as a maintaining dose in patients with acs undergoing des implantation. acs patients undergoing des implantation who receive planned 600mg loading dose clopidogrel pretreatment are eligible for the study. all enrolled patients will be randomized to receive daily clopidogrel 75 mg or 150mg as maintaining doses starting as soon as post-pci, in addition to daily aspirin 100 mg, and lasted for the first month after des implantation. one month later, all patients receive daily clopidogrel 75mg until 9\~12month after des implantation. the primary endpoints include death of all causes, myocardial infarction, revascularization of the target lesson, sub-acute and late stent thrombosis one year after pci, the secondary endpoints are major and minor bleeding events. the study will be powered to test the hypothesis that higher maintaining dose(150mg) of clopidogrel will reduce major adverse cardiac events compared to currently used common dose(75 mg) at one year following pci.


Eligibility criteria:
inclusion criteria: * diagnosed with acs and planned pretreatment with 600mg loading dose of commercially available clopidogrel (plavix). * between ages of 18 years and above * presence of one or several stenosis in native coronary arteries requiring pci and suitable for des implantation. * willing and able to sign informed consent. exclusion criteria: * a history of bleeding diathesis. * new york heart association functional class iv. * prior pci or coronary bypass grafting \< 3 months. * contraindications to clopidogrel and aspirin (white blood cells counts \< 4×109/l or platelet counts \<100 g.l-1 ;creatinine clearance \<25 ml • min-1 ;active liver disease). * use of glycoprotein iib/iiia inhibitors before pci.
feasibility and acceptability of culturally adapted group psychosocial intervention for depressed fathers

Conditions: Depression

Summary: the study is a feasibility trial with a pre and post-experiment design in karachi, pakistan's most populous city. the intervention comprises of twelve sessions of learning through play (ltp) plus during the three month period.


Eligibility criteria:
inclusion criteria: * depressed fathers of children 0-30 months * given written informed consent exclusion criteria: * not willing to participate * out of trial catchment area
comparison of two initial evaluation scales of the severity of brain injury adults patients on the neurological outcome at 6 months

Conditions: Brain Injury

Summary: prospective cohort study. any patient with potential cerebral injured (medical or traumatic) will be included in the study, regardless of its severity, history, the presence of anticoagulant or antiagrégant. the collection should be done as soon as possible, in the reception of vital emergencies or in the urgencies. the collection consists of the realization of a glasgow score and a scale of kremlin-bicêtre for all patients by completing a standardized collection sheet. the collection of gcs and kremlin-bicêtre must be did at the same time. the collection sheet is filled by medical personnel trained. the future of the patient is informed at 6 months using the glasgow outcome scale- extended, which will be made during a following consultation or by phone. additional data will be collected on the folder (ventilation time, days of hospitalization, mortality).


Eligibility criteria:
inclusion criteria: * all patients aged 18 years or more * potentially victim of a cerebral injury whatever the level of severity * having a calculation of gcs and kbs on arrival at the hospital (emergency room) * affiliated to a social security scheme or benefiting through a third person. exclusion criteria: * pregnant women * patients who refusing to participate in research * patients undergoing enhanced protection (persons deprived of liberty by a judicial or administrative decision, adults under legal protection).

Keywords: evaluation scale brain injury severity of brain injury initial evaluation
ovarian function and gynecological profile of patients carrying a pathogenic variant of the hnf1b gene (gyn-hnf1)

Conditions: Genital Diseases, Female

Summary: the main objective of this study is to study the ovarian function of patients with hepatocyte nuclear factor-1beta (hnf1b) abnormality, followed in the reference centers of toulouse and paris university hospitals. the secondary objectives are to know the gynecological profile of these patients. a dosage of anti-mullerian hormone (amh) will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed by the same operator by center. patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. there will be no gynecological examination during this consultation.

hnf1b mutations can be responsible for genital malformations associated with renal development abnormalities. hnf1b is also a candidate gene involved in the development of the renal tract and the mullerian system but there is no data in the literature regarding the ovarian function and clinical gynecological profile of these patients. the main objective of this study is to study the ovarian function of patients with hnf1b abnormality, followed in the reference centers of toulouse and paris university hospitals. the secondary objectives are to know the gynecological profile of these patients. a dosage of amh will be added to the usual balance, whatever the phase of the cycle and a pelvic ultrasound will be performed. patients will be received in a dedicated consultation to complete a questionnaire on gynecological and obstetric history, as well as their personal and family history. there will be no gynecological examination during this consultation.

Eligibility criteria:
inclusion criteria: * girls from 12 years of age carrying a pathogenic variant of the hnf1 b gene and monitored in the reference center for rare renal diseases * person affiliated or beneficiary of a social security scheme. * free, informed and written consent signed by the participant or her legal representative if a minor patient and the investigator (at the latest on the day of inclusion and before any examination required by the research). exclusion criteria: * woman unable to answer * pregnant or breastfeeding woman * refusal of participation by the patient or her legal representative * person under a protection system for adults (such as safeguard of justice, guardianship or curatorship) * history of chemotherapy, radiotherapy, brachytherapy * history of ovarian endometrium

Keywords: gene hnf1b mutation ovarian function genital malformations
follow up of increased nuchal translucency :study of 2010 to 2018 of limoges hospital

Conditions: Ultrasound Fetal Medicine

Summary: the ultrasound of the first trimester allows to determinate the pregnancy beginning, the type of pregnancy and also to detect increased nuchal translucency (nt). fetuses with common chromosomal abnormalities (trisomies 21, 18 and 13 and monosomy x) and structural abnormalities (particularly cardiac defects) and single-gene disorders frequently show increased nt. the purpose of this study is to evaluate in the population of limousin, the type and frequency of these abnormalities.

increased nt superior than 95th percentile (nicolaides curves) during the ultrasound of the first trimester, are associated to common chromosomal abnormalities. it's therefore necessary to make amniocentesis and to analyze karyotyping and genomic microarrays, also known as chromosomal microarrays (cma). in euploid foetus, increased nt is also associated with structural defects or genetic syndromes. additionally, the overall long-term growth of euploid children with increased nt is not much known. the majority (98%) of euploid children with a normal second trimester ultrasound is apparently healthy in the short run. the investigator's objective is to evaluate in a retrospective way, different events (structural defects, chromosomal or genetic abnormalities) during these pregnancies. in a prospective way, the neurodevelopmental disorders in euploid children will be investigated.

Eligibility criteria:
inclusion criteria: * increased nucal translucency (nt) \> 95e percentile on the pregnancy's first trimester * monofoetal pregnancy * twin pregnancy (biamniotic bichorial) * adult patients exclusion criteria: * increased nt \< 95e percentile on the pregnancy's first trimester * increased nt \> 95e percentile on the pregnancy's second trimester * twin pregnancy (biamniotic monochorial), triple or more gestation * underage patients

Keywords: increased nuchal translucency prenatal diagnosis karyotype analysis chromosome micro-array analysis neurodevelopmental disorders euploid children
efficacy and tolerance of nova22007 versus vehicle in patients with vernal keratoconjunctivitis (vkc)

Conditions: Conjunctivitis, Vernal

Summary: the primary objective of this study is: * to assess the efficacy of nova22007, a cyclosporine a (csa), 0.05% and 0.1% versus vehicle in patients with vernal keratoconjunctivitis (vkc) after a 4-week treatment period. the secondary objectives of this study are: * to compare the safety and ocular tolerance of nova22007 0.05% and 0.1%; * to assess the long term safety and ocular tolerance of nova22007 0.05% and 0.1%; and * to assess the decrease in frequency of concomitant artificial tears use.


Eligibility criteria:
inclusion criteria: * at least the two following signs, in at least one eye\* (the same eye should fulfill both criteria): * presence of giant papillae with a diameter ≥ 1 mm on the upper tarsal conjunctiva and * superficial keratitis * at least two of the following ocular symptoms with a score \> 2 in at least one eye\*: burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge, and photophobia. * hyperemia score equal to or greater than 2. exclusion criteria: * concomitant corneal ulcer of infectious origin. * active ocular herpes * disease that could possibly interfere with the interpretation of the study results: active uveitis (defined by tyndall score \> 0), previous history of ocular hypertension or glaucoma, or condition incompatible with the frequent assessments needed by the study. * active herpes. * history of malignancy or a recurrence in the last 5 years. * abnormality of nasolacrimal drainage apparatus. * concomitant disease not stabilized within 1 month before screening visit (e.g. diabetes with glycemia out of range, trouble with thyroid secretions, etc.) or judged by the investigator to be incompatible with the study (e.g. current systemic infections), or condition incompatible with the frequent assessments needed by the study. * known hypersensitivity to one of the components of the investigational medicinal products (imp) or test products. * severe systemic allergy requiring systemic treatment at study entry. * female of childbearing potential. * history of drug or alcohol addiction (\> 50g/day, 5 glasses alcohol/day).

Keywords: vernal keratoconjunctivitis (vkc), eye, allergy, cyclosporin
randomized trial of chlorambucil versus chlorambucil plus rituximab versus rituximab in malt lymphoma

Conditions: Lymphoma, Mucosa-Associated Lymphoid Tissue

Summary: assess the therapeutic activity and safety of the combination of chlorambucil and rituximab in malt lymphomas and determine whether the addition of rituximab to chlorambucil will improve the outcome of malt lymphoma in comparison to treatment with chlorambucil alone. in april 2006, a third arm of treatment was added to compare the antitumor activity and safety of rituximab alone vs chlorambucil alone


Eligibility criteria:
inclusion criteria: 1. histologically proven diagnosis of cd20-positive marginal zone b-cell lymphoma of malt type arisen at any extranodal site 2. any stage (ann arbor i-iv) 3. either de novo, or relapsed disease following local therapy (including surgery, radiotherapy and antibiotics for h. pylori-positive gastric lymphoma) 4. no evidence of histologic transformation to a high grade lymphoma 5. measurable or evaluable disease 6. age \> 18 7. life expectancy of at least 1 year 8. ecog performance status 0-2 9. no prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (cin1) or localized non-melanomatous skin cancer 10. no prior chemotherapy 11. no prior immunotherapy with any anti-cd20 monoclonal antibody 12. no prior radiotherapy in the last 6 weeks 13. no corticosteroids during the last 28 days, unless prednisone chronically administered at a dose \<20 mg/day for indications other than lymphoma or lymphoma-related symptoms 14. no evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry 15. no evidence of symptomatic central nervous system (cns) disease 16. no impairment of bone marrow function (wbc \>3.0x109/l, anc \>1.5x109/l, plt \>100x109/l), unless due to lymphoma involvement 17. no major impairment of renal function (serum creatinine \<1,5x upper normal) or liver function (asat/alat \<2,5 upper normal, total bilirubin \<2,5x upper normal), unless due to lymphoma involvement 18. no evidence of active opportunistic infections 19. no known hiv infection 20. no active hbv and/or hcv infection 21. no pregnant or lactating status 22. appropriate contraceptive method in women of childbearing potential or men 23. absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial 24. informed consent must be given according to national/local regulations before randomization
continuation of drug supply in chinese patients after camn107dbr01study termination

Conditions: Gastrointestinal Stromal Tumor

Summary: continuation of drug supply in chinese patients after camn107dbr01study termination.

five patients who are on treatment of imatinib and deriving clinical benefit after camn107dbr01 study termination and written informed consent obtained will enter the trial, all five patients will receive glivec (8oomg per day) treatment until tumor progression \[by recist guidelines, version 1.0\], unacceptable toxicity, death or withdrawal of consent.

Eligibility criteria:
inclusion criteria: * five patients who are on treatment of imatinib and deriving clinical benefit after camn107dbr01 study termination and written informed consent obtained. exclusion criteria: * n/a.

Keywords: gastrointestinal stromal tumor, gist
effect of obesity among covid-19 patients in critical care settings

Conditions: Obesity; Covid19

Summary: a novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (formerly called hcov-19) emerged in wuhan, china, in late 2019 and is now causing a pandemic. human-to-human transmission is primarily achieved through close contact of respiratory droplets, direct contact with the infected individuals, or by contact with contaminated objects and surfaces. as a new chapter in human life opens up, the world seems to be divided into two parts pre- and post-covid-19 era. body mass index (bmi) is widely used to define obesity and overweight in adults. a bmi between 25 and 30 indicates overweight and above 30 indicates obesity. it is important to note that the levels of the inflammatory cytokines found in obese people are significantly higher than those in lean people, but they are still lower than those in individuals with infection or trauma. obesity-mediated alterations in the airways and immune system are extremely important at the present moment considering sars-cov-2 infection. this study is designed to determine the effect of overweight and obesity with outcomes of patients with moderate to severe covid-19 infection in critical care setting. also, to see outcomes of assisted ventilation in obese patients. this may help in establishing strong association of obesity with covid-19 in our part of the world. this may open new treatment strategies for covid-19 by treating obesity as an essential risk factor.

this prospective cohort study study will be conducted in covid-19 intensive care unit, services hospital lahore. it will be completed in 3 months after approval of proposal taking 100 patients using non probability purposive sampling. after ethical approval, research will be started and patients will be recruited from icu according to inclusion and exclusion criteria. patients will be randomized to two groups group a with normal bmi and group b having over weight and obese patients. they will be given standard treatment as practiced and outcome will be measured in terms of recovery from disease or death. duration of stay in hospital, progression of disease, o2 requirement, improvement in biochemical profile and radiology or occurrence of complications. data will be put in spss version 25 and analysis will be done.

Eligibility criteria:
inclusion criteria: 1. all patients presented to icu with pcr positive for covid-19 . 2. both genders included. 3. age range 18 to 80 years. 4. patients fulfilling criteria for moderate to severe disease. 5. conscious patient on initial presentation. 6. bmi range from 18-\> 40. exclusion criteria: 1. unable to provide free informed consent. 2. pregnant females. 3. gross ascites, amputation or other conditions making bmi measurement unreliable.

Keywords: obesity covid-19 assisted ventilation
prospective assessment after pediatric cardiac ablation (papca)

Conditions: Cardiovascular Diseases; Heart Diseases; Arrhythmia; Tachycardia, Supraventicular

Summary: to evaluate children undergoing catheter ablation at pediatric centers in north america in order to provide information on the incidence rate of serious cardiac damage as a result of ablation, the incidence rate and time course of recurrence after initially successful ablation, and the incidence rate of proarrhythmia following ablation.

background: radiofrequency catheter ablation is a catheterization laboratory technique for the cure of cardiac arrhythmias, which has become common in pediatric cardiology practice. recent analyses have suggested that ablation therapy is more cost-effective compared not only with surgery, but also with antiarrhythmic medication. despite a good initial success rate of the technique, and a low initial complication rate, there is concern about possible long-term effects with the technique in the pediatric age group. there are reports not only of damage to cardiac valves, but also the development of new arrhythmias, including sudden death, as a result of ablations in children. recurrences are observed frequently following initially successful procedures. finally, there are animal data to suggest that immature myocardium is more prone to severe damage as a result of ablation procedures. few, if any, data exist to support the long-term safety of these ablation techniques in children. therefore, before ablation therapy becomes the standard approach in children, it is important to carefully assess the long-term risks in this patient group. design narrative: multi-center, prospective, five-year study. the collection of these data was intended to provide the following information: 1) the incidence of serious cardiac damage as a result of ablation; 2) the incidence and time course of recurrence after initially successful ablation; and 3) the incidence of proarrhythmia following ablation. a total of 480 pediatric patients were enrolled prospectively and evaluated both before ablation of supraventricular tachycardia and at intervals following ablation with clinical history and examination, electrocardiogram, 24-hour holter monitor, and echocardiogram, with non-invasive studies read by outside consultants. in addition, a complete registry of pediatric patients undergoing ablation at the participating centers was established to allow comparisons with the study group and to provide population estimates of success and complication rates.

Eligibility criteria:
no eligibility criteria
clinical mr spectroscopy of brain metastases at 1,5t and 3t.

Conditions: Neoplasm Metastases

Summary: increasing magnetic field is known to give improvements in signal-to-noise-ratio (snr) and spectral resolution. to investigate this, spectra from different subjects were examined using two clinical mr instruments operating at 1.5t and 3t respectively.


Eligibility criteria:
inclusion criteria: * brain metastases exclusion criteria: * children * pregnancy

Keywords: brain metastasis signal to noise ratio spectral resolution